Summary of Study ST001748
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001120. The data can be accessed directly via it's Project DOI: 10.21228/M8XM6R This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001748 |
| Study Title | Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis |
| Study Type | Targeted metabolomics |
| Study Summary | GUT103 and GUT108, live biotherapeutic products rationally designed to complement missing or underrepresented functions in the dysbiotic microbiome of IBD patients; they address upstream targets, rather than targeting a single cytokine to block downstream inflammation responses. Systematic colonization experiments in colitis mouse models were performed to test their therapeutic effects. Targeted fecal metabolomics data uploaded here of bile acids, short-chain fatty acids, and tryptophan metabolites provides a unique metabolome perspective for evaluation of the therapeutic potential of GUT103 and GUT108. |
| Institute | University of North Carolina at Chapel Hill |
| Laboratory | Gusto Global LLC. |
| Last Name | Lai |
| First Name | Yunjia |
| Address | 1104 MHRC, 135 Dauer Drive, Chapel Hill, NC 27599, USA |
| lai7@live.unc.edu | |
| Phone | +1 919-480-5489 |
| Submit Date | 2021-04-22 |
| Num Groups | 12 |
| Publications | Nature Communications |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzXML |
| Analysis Type Detail | GC-MS/LC-MS |
| Release Date | 2021-04-30 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001120 |
| Project DOI: | doi: 10.21228/M8XM6R |
| Project Title: | Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis |
| Project Type: | targeted metabolomics |
| Project Summary: | Environmental factors, mucosal permeability and defective immunoregulation drive overactive immunity to a subset of resident intestinal bacteria that mediate multiple inflammatory conditions. GUT-103 and GUT-108, live biotherapeutic products rationally designed to complement missing or underrepresented functions in the dysbiotic microbiome of IBD patients, address upstream targets, rather than targeting a single cytokine to block downstream inflammation responses. GUT-103, composed of 17 strains that synergistically provide protective and sustained engraftment in the IBD inflammatory environment, prevented, and treated chronic immune-mediated colitis. Therapeutic application of GUT-108 reversed established colitis in a humanized chronic T cell-mediated mouse model. It decreased pathobionts while expanding resident protective bacteria; produced metabolites promoting mucosal healing and immunoregulatory responses; decreased inflammatory cytokines and Th-1 and Th-17 cells; and induced interleukin-10-producing colonic regulatory cells, and IL-10-independent homeostatic pathways. We propose GUT-108 for treating and preventing relapse for IBD and other inflammatory conditions characterized by unbalanced microbiota and mucosal permeability. |
| Institute: | University of North Carolina at Chapel Hill |
| Department: | UNC Departments of Medicine, Microbiology and Immunology, Center for Gastrointestinal Biology and Disease; UNC Department of Environmental Sciences and Engineering |
| Laboratory: | R. Balfour Sartor Lab; Kun Lu Lab |
| Last Name: | Lai |
| First Name: | Yunjia |
| Address: | 1104 MHRC, 135 Dauer Drive, NC |
| Email: | lai7@live.unc.edu |
| Phone: | 919-480-5489 |
| Funding Source: | Gusto Global LLC.; National Institute of Health (NIH) (grant no. P40OD010995; P30DK034987; P01DK094779); the Crohn’s and Colitis Foundation |
| Publications: | Nature Communications |
